CLINICAL EVALUATION OF THE HEPARIN-COATED CARDIOPULMONARY BYPASS SYSTEM

• Published in: Jinko Zoki Vol. 23; no. 1; pp. 309 - 312
• Main Authors: MASUDA, H., TOYOHIRA, H., MORIYAMA, Y., SAIGENJI, H., SHIMOKAWA, S., TAIRA, A.
• Format: Journal Article
• Language: Japanese
• Published: JAPANESE SOCIETY FOR ARTIFICIAL ORGANS 1994
• Subjects: complement; heparin-coated cardiopulmonary bypass; platelet; red cell deformability; thrombin
• ISSN: 0300-0818; 1883-6097
• DOI: 10.11392/jsao1972.23.309

To clarify the efficacy of the heparin-coated cardio-pulmonary bypass system incorporating with low-dose heparinazation, blood-material interactions in a standard open-heart surgery were examined. Two groups (heparin-coated system group; n=7, initial dose=2mg/kg and additional dose=1mg/kg, non-coated system group; n=7, initial dose=3mg/kg) were compared each other with several items. There was no difference in the rate of thrombin formation (reflected in thrombin-antithrombin III complex) during the cardio-pulmonary bypass despite the significant difference in heparin concentration between the groups. Platelet (count, beta-TG, aggregation rate) and complement (C3a) activation during the bypass tended to be more prominent in the non-coated group. Red cell deformability, which was assessed with red cell filtration rate, was significantly better in the heparin-coated group. We conclude that usefulness of the heparin-coated cardiopulmonary bypass system is preserved even under the low-dose heparinization in the standard open-heart surgery.